The Indonesian pharmaceutical and biopharmaceutical sector has demonstrated a highly resilient performance in mid-2026, anchored by a successful international trade delegation facilitated by the Indonesian Economic and Trade Office (KDEI) in Taipei under the Ministry of Trade. Participating in the Biotechnology Innovation Organization (BIO) Asia-Taiwan 2026 exhibition at the Taipei Nangang Exhibition Center, seven national healthcare companies secured potential trade transactions worth USD 2 million (approximately IDR 34 billion). This milestone reflects strong Asian demand for Indonesian biopharmaceutical raw materials, natural health extracts, advanced laboratory services, and medical equipment.

This strong commercial output bolsters Indonesia's position as an emerging pharmaceutical and health technology hub within East Asia and ASEAN. Healthcare equity analysts, specialized medical supply chain coordinators, and global pharmaceutical procurement officers should monitor these capacity indicators closely, as Indonesia’s expanded biopharmaceutical production capabilities and strategic Asian trade channels are actively re-routing health technology distribution metrics across international trade lanes.
Source:
https://www.kemendag.go.id/berita/perdagangan/produk-farmasi-dan-kesehatan-indonesia-raih-potensi-transaksi-rp34-miliar-di-pameran-kesehatan-taiwan